Arsenic Trioxide PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1327-53-3
Molecular formula
As2O3
Molecular weight
197.841 g/mol
Drug class
Antineoplastic differentiating agentarsenical cytotoxic drug
Mechanism of action
In acute promyelocytic leukaemia (APL), arsenic trioxide promotes degradation of the PML-RARα fusion oncoprotein and induces differentiation and apoptosis of abnormal promyelocytes. Additional cellular effects contribute to antineoplastic activity.
Indications / reported uses
Treatment of newly diagnosed low-risk acute promyelocytic leukaemia (APL) in combination with tretinoin
Treatment of relapsed or refractory APL in product-specific regimens under specialist haematology care
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Arsenic Trioxide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Arsenic Trioxide Permitted Daily Exposure (PDE) report (the Arsenic Trioxide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Arsenic Trioxide Occupational Exposure Limit (OEL) report (the Arsenic Trioxide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.